472964-40-2

Upstream product

• 128796-39-4 4-trifluoromethylphenylboronic acid 
• 39959-54-1 3-bromobenzylamine hydrochloride 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 10269-01-9 3-bromobenzylamine 

Downstream Products

• 1257437-16-3 2S-[(4'-trifluoromethyl-biphenyl-3-ylmethyl)-carbamoyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1590397-04-8 2-[cyclopropyl-(4-fluorobenzenesulfonyl)amino]-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590397-05-9 2-[ethyl-(4-fluorobenzenesulfonyl)amino]-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590397-06-0 2-cyclopropyl-2-(4-fluorobenzenesulfonylamino)-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590397-34-4 (S)-2-[(4-fluorobenzenesulfonyl)(methyl)amino]-3-methoxy-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)propionamide 
• 1590396-84-1 (S)-2-[(4-fluoro-benzenesulfonyl)methylamino]-N-(4’-trifluoromethylbiphenyl-3-ylmethyl)propionamide 
• 1590397-42-4 2-[(4-fluorobenzenesulfonyl)-oxetan-3-yl-amino]-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590396-95-4 2-[(4-fluorobenzenesulfonyl)-(2,2,2-trifluoroethyl)amino]-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590396-83-0 2-[(4-fluoro-benzenesulfonyl)-methyl-amino]-N-(4’-trifluoromethyl-biphenyl-3-ylmethyl)-acetamide 
• 1590397-01-5 2-[(4-fluorobenzenesulfonyl)-(2-hydroxyethyl)amino]-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590397-02-6 2-[(4-fluorobenzenesulfonyl)-(2-hydroxypropyl)amino]-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590397-80-0 tert-butyl cyclopropyl(2-oxo-2-((4'-(trifluoromethyl)biphenyl-3-yl)methylamino)ethyl)carbamate 
• 1590396-89-6 2-[(4-fluorobenzenesulfonyl)-methylamino]-2-methyl-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)propionamide 
• 1590397-36-6 2-[(4-fluorobenzenesulfonyl)-oxetan-3-ylmethylamino-N-(4'-trifluoron-3-ylmethylamino)]-N-(4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 

Relevant academic research and scientific papers

Novel sulfonamide TRPA1 receptor antagonists

The invention discloses compounds of Formula I The compounds of formula I are TRPA1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of TRPA1 receptors.

NOVEL SULFONAMIDE TRPA1 RECEPTOR ANTAGONISTS

The invention discloses compounds of Formula (I). The compounds of formula (I) are TRPA1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of TRPA1 receptors.

SUBSTITUTED SULFONAMIDE COMPOUNDS

The invention is concerned with the compounds of formula (I), and salts thereof, wherein X, Y, Z, R1, R2, R3, R3, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1

Certain heterocyclic amide compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPA1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.